Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma

Summary

Background: \- Imetelstat is a cancer treatment drug that may slow or stop tumor growth. It may also prevent tumors from spreading to other parts of the body. Researchers want to see if it can be a safe and effective treatment for children who have solid tumors or lymphoma that have not responded to other treatments. Objectives: \- To see if imetelstat is a safe and effective treatment for children who have solid tumors or lymphoma that have not responded to other treatments. Eligibility: \- Children and adolescents between 1 and 21 years of age who have solid tumors or lymphoma that have not responded to other treatments. Design: * Participants will be screened with a physical exam, medical history, and imaging studies. Blood and urine samples will also be collected. * Participants will receive imetelstat on the first and eighth day of a 21-day cycle of treatment. * Treatment will be monitored with frequent blood tests and imaging studies. Tumor biopsies may also be performed. * Participants will keep taking the study drugs for up to a total of 18 cycles as long as the disease does not progress and there are no severe side effects....

Timeline

Start

2012-03

Primary completion

—

Completion

2012-10

Publications

• Background Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990 May 31;345(6274):458-60. doi: 10.1038/345458a0.
• Background Harley CB. Telomerase is not an oncogene. Oncogene. 2002 Jan 21;21(4):494-502. doi: 10.1038/sj.onc.1205076.
• Background Bosoy D, Peng Y, Mian IS, Lue NF. Conserved N-terminal motifs of telomerase reverse transcriptase required for ribonucleoprotein assembly in vivo. J Biol Chem. 2003 Feb 7;278(6):3882-90. doi: 10.1074/jbc.M210645200. Epub 2002 Nov 27.

Drugs

Indications